Flindr Therapeutics
Maarten Ligtenberg is the Chief Executive Officer at Flindr Therapeutics since March 2020, leading the development of innovative precision oncology medicines through the Immunogram Drug Discovery Engine. Prior to this role, Maarten served as a Postdoctoral Researcher at The Netherlands Cancer Institute from October 2015 to July 2020, and as a PhD Candidate at Karolinska Institutet from September 2010 to September 2015, focusing on passive and active immunity in immunotherapy, particularly through DNA vaccination. Maarten's earlier academic experience includes an MSc internship at Karolinska Institutet and an MSc thesis position at Wageningen University, culminating in degrees from Wageningen University & Research and a Doctor of Philosophy in Tumor Immunology from Karolinska Institutet.
This person is not in any teams
Flindr Therapeutics
Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Innovatiefonds Noord Holland, and BOM. Flindr has entered into a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology).